Alarin is a newly identified member of the galanin family of neuropeptides. Until now, research on alarin is limited compared with other members of the galanin family. Unearthing the new biological effects of alarin and its unidentified receptor(s) interests us. We previously showed that alarin has an effect on depression-like behaviors, although the underlying mechanisms are not fully clarified. The present study verified the antidepressant-like effects of alarin using the unpredictable chronic mild stresses (UCMS) paradigm, and explored the mechanism that underlies antidepressant-like effects of alarin in mice. Previous research has shown that TrkB receptor-mediated ERK and AKT signaling pathways participate in depression pathophysiology. Therefore, we aimed to explore whether alarin improved depression-like behaviors by increasing activity of ERK and AKT pathways mediated by TrkB. Results showed that alarin significantly reduced immobility time in the forced swim test and latency to feed in the novelty suppressed feeding test. In addition, decreased p-ERK/ERK and p-AKT/AKT levels in the prefrontal cortex, hippocampus, olfactory bulb, and hypothalamus induced by UCMS were reversed by intracerebroventricular injection of alarin. Results suggested that alarin increased p-ERK/ERK and p-AKT/AKT levels by acting on the TrkB receptor. To verify this hypothesis, mice were pretreated with the TrkB inhibitor K252a (or 0.1% dimethyl sulfoxide, intraperitoneally, 3 days), followed by intracerebroventricular injection of alarin. This resulted in an absence of antidepressant-like effects, as well as no activation of ERK and AKT signaling pathways. Results demonstrate that alarin may exert antidepressant-like effects by targeting TrkB receptor-mediated ERK and AKT signal systems, which could help to identify the alarin receptor.
Keywords: AKT; Alarin; Depression; Extracellular signal-regulated kinase; cAMP-response element binding protein.
Copyright © 2014 Elsevier B.V. All rights reserved.